Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions

Healthy Participants

Interventions

DRUG

Brazikumab

Participants will receive IV or SC injection of brazikumab as per the group they are assigned.

Trial Locations (1)

Research Site, Glendale